What type of study is this?

September 10, 2025Scientific ReportsOpen Access

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis

View Full Paper

Ask AI

Bookmark

High-dose UC-MSCs combined with pirfenidone improved pulmonary function in mice with fibrosis.
Key metrics showed that the combined treatment significantly reduced pro-fibrotic gene expression levels (P < 0.05).
The approach involved a bleomycin-induced model and assessed pulmonary function, histopathology, and inflammatory factors.
The findings highlight a promising combined therapy for pulmonary fibrosis, with significant effects seen in animal models.

No takes yet. Share an insight, caveat, or question.

This study demonstrates that pirfenidone and UC-MSCs improve fibrosis in mice, suggesting a new PF treatment strategy.

Xu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark